Analyst Price Targets — VOR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 12:00 pm | Martin Fan | Wedbush | $18.00 | $15.22 | TheFly | Vor Bio price target raised to $18 from $15 at Wedbush |
| April 15, 2026 10:03 am | — | H.C. Wainwright | $31.00 | $15.87 | TheFly | Vor Bio price target lowered to $31 from $32 at H.C. Wainwright |
| December 23, 2025 11:59 am | — | Robert W. Baird | $46.00 | $13.71 | TheFly | Vor Bio price target lowered to $46 from $64 at Baird |
| October 29, 2025 12:23 pm | — | H.C. Wainwright | $55.00 | $26.93 | TheFly | Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split |
| October 14, 2025 9:10 pm | — | Robert W. Baird | $64.00 | $30.81 | TheFly | Vor Bio upgraded to Outperform from Neutral at Baird |
| September 24, 2025 12:56 am | Stephen Willey | Stifel Nicolaus | $55.00 | $31.28 | TheFly | Vor Bio upgraded to Buy from Hold at Stifel |
| June 30, 2025 10:07 am | — | H.C. Wainwright | $3.00 | $1.62 | TheFly | Vor Bio upgraded to Buy from Neutral at H.C. Wainwright |
| April 27, 2022 6:14 am | — | Goldman Sachs | $6.00 | $5.60 | Benzinga | Goldman Sachs Initiates Coverage On Vor Biopharma with Neutral Rating, Announces Price Target of $6 |
Latest News for VOR
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. With more than 20 years of biopharmaceutical leadership experience, Dr. Zaccardelli has successfully built and led companies through late-stage development, regulatory…
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitacicept, a dual BAFF/APRIL inhibitor with multiple China approvals. VOR holds $491.5 million in cash, providing runway through early 2029 and enabling Phase 3 clinical trial readouts in gMG and Sjögren's disease before requiring additional capital. Telitacicept's differentiation lies in upstream B-cell pathway…
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate…
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 71,200 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate…
First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and clinically meaningful improvements in both ESSDAI and ESSPRI SjD marks the fifth indication approval for telitacicept BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VOR.
U.S. House Trading
No House trades found for VOR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.